{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:20:57Z","timestamp":1775460057674,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018736","name":"Kaken Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15H04758"],"award-info":[{"award-number":["15H04758"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16H05114"],"award-info":[{"award-number":["16H05114"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.heliyon.2024.e25485","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T01:24:31Z","timestamp":1706837071000},"page":"e25485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"10","author":[{"given":"Ryota","family":"Murata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-4144","authenticated-orcid":false,"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Chikamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6223-5337","authenticated-orcid":false,"given":"Isamu","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5796-7055","authenticated-orcid":false,"given":"Kengo","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayano","family":"Nishinoiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Yoshitake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Nosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-9468","authenticated-orcid":false,"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e25485_bib1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib2","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e25485_bib3","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111S","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.heliyon.2024.e25485_bib4","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.3350\/cmh.2022.0437","article-title":"Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials","volume":"29","author":"An","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib5","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib6","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/hep.27921","article-title":"Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1","volume":"62","author":"Chang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hep.30822","article-title":"Hepatocyte TNF receptor-associated factor 6 aggravates hepatic inflammation and fibrosis by promoting lysine 6-linked polyubiquitination of apoptosis signal-regulating kinase 1","volume":"71","author":"Wang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib12","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1073\/pnas.051454398","article-title":"Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems","volume":"98","author":"Sun","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e25485_bib13","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1074\/jbc.272.5.2936","article-title":"Cloning and expression of a novel mammalian thioredoxin","volume":"272","author":"Spyrou","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e25485_bib14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1053\/j.gastro.2006.08.023","article-title":"Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production","volume":"131","author":"Tamaki","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/ATVBAHA.112.249334","article-title":"Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis","volume":"32","author":"El Hadri","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib16","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1093\/emboj\/17.9.2596","article-title":"Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1","volume":"17","author":"Saitoh","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.heliyon.2024.e25485_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0168-8278(02)00331-8","article-title":"Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"38","author":"Sumida","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2010.05.020","article-title":"Albumin fusion of thioredoxin--the production and evaluation of its biological activity for potential therapeutic applications","volume":"147","author":"Ikuta","year":"2010","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.heliyon.2024.e25485_bib19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ki.2012.429","article-title":"A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy","volume":"83","author":"Kodama","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.heliyon.2024.e25485_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75025-5","article-title":"Systemic and sustained thioredoxin analogue prevents acute kidney injury and its-associated distant organ damage in renal ischemia reperfusion injury mice","volume":"10","author":"Nishida","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e25485_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115600","article-title":"Recombinant long-acting thioredoxin ameliorates AKI to CKD transition via modulating renal oxidative stress and inflammation","volume":"22","author":"Nishida","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e25485_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030562","article-title":"Long-acting thioredoxin ameliorates doxorubicin-induced cardiomyopathy via its anti-oxidative and anti-inflammatory action","volume":"14","author":"Murata","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.heliyon.2024.e25485_bib23","article-title":"A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis","volume":"4","author":"Ejima","year":"2016","journal-title":"Phys. Rep."},{"key":"10.1016\/j.heliyon.2024.e25485_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2023.01.039","article-title":"Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease","volume":"355","author":"Chikamatsu","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.heliyon.2024.e25485_bib25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.34067\/KID.0000772019","article-title":"Advanced oxidation protein products contribute to renal tubulopathy","volume":"1","author":"Imafuku","year":"2020","journal-title":"Kidney"},{"key":"10.1016\/j.heliyon.2024.e25485_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102371","article-title":"A bioinspired carbon monoxide delivery system prevents acute kidney injury and the progression to chronic kidney disease","volume":"54","author":"Nagasaki","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68337-z","article-title":"A synthetic retinoic acid receptor agonist Am80 ameliorates renal fibrosis via inducing the production of alpha-1-acid glycoprotein","volume":"10","author":"Watanabe","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e25485_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.metabol.2017.04.012","article-title":"Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population","volume":"73","author":"Zheng","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.heliyon.2024.e25485_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107609","article-title":"Neutrophil: an emerging player in the occurrence and progression of metabolic associated fatty liver disease","volume":"97","author":"Chen","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2024.e25485_bib31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.heliyon.2024.e25485_bib32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell Metabol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.tem.2017.10.003","article-title":"Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism","volume":"28","author":"Aljohani","year":"2017","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib34","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of mitochondria in nonalcoholic fatty liver disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e25485_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqz046","article-title":"CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential","volume":"161","author":"Schlaepfer","year":"2020","journal-title":"Endocrinology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib36","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.21752","article-title":"Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes","volume":"46","author":"Joshi-Barve","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e25485_bib37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1006\/bbrc.2000.3689","article-title":"Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions","volume":"277","author":"Das","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2024.e25485_bib38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.addr.2009.01.003","article-title":"Thioredoxin 1 delivery as new therapeutics","volume":"61","author":"Nakamura","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2024.e25485_bib39","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.93.3.1006","article-title":"A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity","volume":"93","author":"Tamura","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e25485_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/377068a0","article-title":"MIF as a glucocorticoid-induced modulator of cytokine production","volume":"377","author":"Calandra","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e25485_bib42","first-page":"1","article-title":"Pathophysiological roles of ASK1-MAP kinase signaling pathways","volume":"40","author":"Nagai","year":"2007","journal-title":"J. Biochem. Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/jcp.21172","article-title":"Liver regeneration","volume":"213","author":"Michalopoulos","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.heliyon.2024.e25485_bib44","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.20969","article-title":"Liver regeneration","volume":"43","author":"Fausto","year":"2006","journal-title":"Hepatology"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024015160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024015160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:35:14Z","timestamp":1775457314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024015160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2405844024015160"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25485","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e25485"}}